{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Butler CC"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)","Wellcome Trust"],"pagination":["281-293"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9779781"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["401(10373)"],"pubmed_abstract":["<h4>Background</h4>The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.<h4>Methods</h4>PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older-or aged 18 years or older with relevant comorbidities-and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive "],"journal":["Lancet (London, England)"],"pubmed_title":["Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial."],"pmcid":["PMC9779781"],"funding_grant_id":["CL-2009-13-006","NF-SI-0616-10103","NIHR-INF-2784","NIHR203799","NIHR202402","MR/M008665/1","216421/Z/19/Z","MR/W015560/1","NIHR203701","CL-2016-17-007","NIHR300105","G1001128","MC_UU_00004/04","NIHR135366","CL-2022-13-005","NF-SI-0611-10273"],"pubmed_authors":["Wilson P","Nguyen-Van-Tam JS","Mort S","Patel A","Agyeman AA","Allcock D","Standing JF","Ahmed T","Ogundapo O","Frost E","Poonian S","Little P","Shah D","Woods S","Okeke H","Ahmed H","Benedict OE","Hart ND","Gbinigie OA","Thalasselis C","Butler M","Patel K","Hayward G","Richardson S","Lowe DM","Chalk J","Nally R","Lester N","Murphy D","Saville BR","Andersson M","Fox R","Rahman NM","Granier S","Danson R","Breuer J","Bateman C","Dickson J","Fisher S","Coates M","Lee R","Soni Y","Hobbs FDR","Lunn J","Hood K","Sheikh A","Cheng Z","Irving G","Kennard J","Mathukia M","Davies JC","Hutchinson S","Sidhu BS","Bird N","Wong M","Patel MG","Lown M","Lavallee L","Butler D","McKenna M","Law T","Sehdev S","Richards DB","Ghosh S","Allen J","van Hecke O","Carson-Stevens A","Morton S","Goodman A","Dorward J","Jani BD","Prasad V","Mwandigha L","Prasad R","Imlach M","Butler CC","Wingfield D","Evans P","Singh I","PANORAMIC Trial Collaborative Group","Engamba S","Hussain I","Dhasmana D","Beltran-Martinez A","Fitzgerald M","Safa A","Gilkar I","Royal S","Ndukauba C","Madden TA","Howell A","Saunders CT","Raymundo-Wood I","Penfold R","Wooding N","Gaunt R","Lewis D","Thomas NPB","Brennan L","Krasucki C","Popoola O","Ustianowski A","Berry NS","Petrou S","Png ME","Marion J","Francis N","Galal U","Barrett S","Ogburn E","Cureton L","Zafar A","de Kare-Silver N","Razzaq O","Holmes J","Jacobsen N","Rutter H","Woodall MNJ","Harris V","Knox K","Moore P","Hadley E","Dobson M","Detry MA","Yongblah F","Yong J","Brown J","Burns G","Khoo S","Sevenoaks T","Mackintosh CI","Pora A","Short V","Khan U","Yu LM","Benysek M"],"additional_accession":[]},"is_claimable":false,"name":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.","description":"<h4>Background</h4>The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.<h4>Methods</h4>PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older-or aged 18 years or older with relevant comorbidities-and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-03-17T16:16:32.69Z","creation":"2025-02-19T00:47:42.829Z"},"accession":"S-EPMC9779781","cross_references":{"pubmed":["36566761"],"doi":["10.1016/S0140-6736(22)02597-1"]}}